9:27 AM ET
8-K
Investor Presentation
Acumen Pharmaceuticals Investor Presentation
Acumen Pharmaceuticals is hosting an Investor Day on September 16, 2026, to discuss its strategic goals and clinical pipeline, including its product candidate sabirnetug (ACU193) for Alzheimer's Disease. The presentation covers the Phase 2 ALTITUDE-AD study, potential subcutaneous dosing options, and the company's Enhanced Brain Delivery (EBD) technology with a planned IND filing in mid-2027.